Giant Biogene Holding Co., Ltd. (HKEX: 02367) reported no changes to its authorised, issued or treasury share balances for the month ended 31 July 2026, according to the company’s latest monthly return filed on 4 August 2026.
Authorised and Issued Capital • Authorised share capital remained at 5.00 billion ordinary shares with a par value of USD 0.00001 each, representing total authorised capital of USD 50,000. • Issued shares stood unchanged at 1.06 billion, with no treasury shares on record. Consequently, total issued share capital also stayed flat month-on-month.
Public Float Status The company confirmed compliance with the Hong Kong Main Board’s minimum 25% public-float requirement as at 31 July 2026.
Share Option Activity • Under the 2023 Share Option Scheme (adopted 17 Aug 2023), 10.93 million options were outstanding at month-end, identical to the previous month. • No new shares were issued and no treasury shares were transferred pursuant to option exercises, resulting in zero proceeds raised during the period. • The scheme still permits issuance of up to 80.89 million additional shares upon future option grants.
Other Equity Instruments The filing shows no outstanding or new warrants, convertible securities, or other share-issuance arrangements, and no share repurchases or redemptions occurred during the month.
Governance Confirmation Executive Director and Joint Company Secretary Yan Yubo affirmed that all regulatory requirements and listing rules were met for the period under review.
Comments